Wilson's disease medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 25: | Line 25: | ||
==Medical therapy== | ==Medical therapy== | ||
* The mainstay stay of therapy for treatment of Wilson's disease is the medical therapy. <ref name="Walshe1996">{{cite journal |author=Walshe JM |title=Treatment of Wilson's disease: the historical background |journal=QJM |volume=89 |issue=7 |pages=553–5 |year=1996|month=July |pmid=8759497}}</ref> | |||
* The treatment of Wilson's disease is accomplished through two mechanisms: | |||
** Removing of the excess copper in the body by copper chelators | |||
** Preventing reaccumulation of the copper | |||
* '''Removal of the copper:''' | |||
** Preferred regimen (1): D-penicillamine 20 mg/kg PO q12h | |||
** Alterantive regimen (1): Trientine hydrochloride 500 to 750 mg PO q12h/q6h | |||
* '''Preventing reaccumulation:''' | |||
** Preferred regimen (1): Zinc acetate PO 50 mg q8h | |||
==References== | ==References== |
Revision as of 02:52, 26 December 2017
Wilson's disease Microchapters |
Diagnosis |
---|
Treatment |
Wilson's disease medical therapy On the Web |
American Roentgen Ray Society Images of Wilson's disease medical therapy |
Risk calculators and risk factors for Wilson's disease medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Recommendations for the treatment of Wilson's Disease (DO NOT EDIT)
“ |
Treatment in Specific Clinical Situations
Treatment Targets and Monitoring of Treatment
|
” |
Medical therapy
- The mainstay stay of therapy for treatment of Wilson's disease is the medical therapy. [1]
- The treatment of Wilson's disease is accomplished through two mechanisms:
- Removing of the excess copper in the body by copper chelators
- Preventing reaccumulation of the copper
- Removal of the copper:
- Preferred regimen (1): D-penicillamine 20 mg/kg PO q12h
- Alterantive regimen (1): Trientine hydrochloride 500 to 750 mg PO q12h/q6h
- Preventing reaccumulation:
- Preferred regimen (1): Zinc acetate PO 50 mg q8h